Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.61B |
| 2 |
Microsoft
MSFT
|
+$1.17B |
| 3 |
Broadcom
AVGO
|
+$366M |
| 4 |
Merck
MRK
|
+$343M |
| 5 |
Meta Platforms (Facebook)
META
|
+$260M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$609M |
| 2 |
CMA
Comerica
CMA
|
+$512M |
| 3 |
CADE
Cadence Bank
CADE
|
+$422M |
| 4 |
Johnson & Johnson
JNJ
|
+$331M |
| 5 |
Western Digital
WDC
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.81% |
| 2 | Financials | 17.07% |
| 3 | Industrials | 12.54% |
| 4 | Consumer Discretionary | 10.14% |
| 5 | Healthcare | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Ascent Industries
ACNT
$138M
| $3.77M | ﹤0.01% |
283,567
-86,623
| -23% | -$1.34M |
|
|
BIOA
2577
BioAge Labs
BIOA
$928M
| $3.75M | ﹤0.01% |
+214,546
| New | +$4.13M |
|
2578
Taylor Devices
TAYD
$178M
| $3.75M | ﹤0.01% |
65,657
-3,886
| -6% | -$299K |
|
2579
Aura Biosciences
AURA
$741M
| $3.73M | ﹤0.01% |
558,158
+40,242
| +8% | +$231K |
|
2580
Mineralys Therapeutics
MLYS
$2.4B
| $3.72M | ﹤0.01% |
137,433
-203
| -0.1% | -$5.95K |
|
2581
Resources Connection
RGP
$133M
| $3.71M | ﹤0.01% |
994,169
-298,160
| -23% | -$1.22M |
|
2582
MainStreet Bancshares
MNSB
$167M
| $3.7M | ﹤0.01% |
166,633
+28,282
| +20% | +$610K |
|
2583
Cricut
CRCT
$940M
| $3.69M | ﹤0.01% |
985,868
+229,663
| +30% | +$1.01M |
|
2584
USCB Financial Holdings
USCB
$413M
| $3.69M | ﹤0.01% |
198,845
+26,267
| +15% | +$500K |
|
2585
Medifast
MED
$110M
| $3.69M | ﹤0.01% |
361,762
+35,522
| +11% | +$383K |
|
2586
Mercer International
MERC
$44.8M
| $3.63M | ﹤0.01% |
2,554,086
-265,188
| -9% | -$506K |
|
2587
Everspin Technologies
MRAM
$351M
| $3.59M | ﹤0.01% |
409,010
+46,929
| +13% | +$517K |
|
2588
Larimar Therapeutics
LRMR
$397M
| $3.59M | ﹤0.01% |
798,462
+470,968
| +144% | +$1.88M |
|
2589
Keros Therapeutics
KROS
$202M
| $3.55M | ﹤0.01% |
321,360
+263,347
| +454% | +$4.07M |
|
2590
Microvast
MVST
$266M
| $3.54M | ﹤0.01% |
2,363,006
+1,314,060
| +125% | +$3.16M |
|
2591
OptimizeRx
OPRX
$120M
| $3.54M | ﹤0.01% |
563,570
+102,661
| +22% | +$953K |
|
2592
3D Systems Corp
DDD
$430M
| $3.54M | ﹤0.01% |
1,881,311
+320,427
| +21% | +$712K |
|
2593
Cadeler
CDLR
$2.16B
| $3.54M | ﹤0.01% |
150,345
-74,153
| -33% | -$1.75M |
|
2594
Tyra Biosciences
TYRA
$1.85B
| $3.52M | ﹤0.01% |
91,826
-3,814
| -4% | -$123K |
|
2595
Simulations Plus
SLP
$371M
| $3.47M | ﹤0.01% |
293,940
-54,294
| -16% | -$800K |
|
2596
FTAI Infrastructure
FIP
$489M
| $3.47M | ﹤0.01% |
702,803
-274,700
| -28% | -$1.54M |
|
2597
ATS Corp
ATS
$2.58B
| $3.45M | ﹤0.01% |
122,456
+12,114
| +11% | +$364K |
|
2598
Aehr Test Systems
AEHR
$2.52B
| $3.44M | ﹤0.01% |
93,037
-16,030
| -15% | -$513K |
|
2599
DMC Global
BOOM
$117M
| $3.4M | ﹤0.01% |
651,838
-3,298
| -0.5% | -$23K |
|
2600
Paysign
PAYS
$496M
| $3.4M | ﹤0.01% |
575,619
+82,736
| +17% | +$335K |
|
Similar funds
Dimensional Fund Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Dimensional Fund Advisors held 3,312 positions worth $481B, up 0.98% from $477B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Dimensional Fund Advisors's Q1 2026 filing shows 72 new, 1,935 increased, 1,135 reduced and 97 closed positions. Its largest new stake was Versant Media Group: 1,127,961 shares worth $41.7M. The largest sale was AstraZeneca, an estimated $609M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Financials and Industrials.
- Dimensional Fund Advisors's largest Q1 2026 buy was Versant Media Group: 1,127,961 shares worth $41.7M.
- Dimensional Fund Advisors added most to Amazon in Q1 2026, an estimated $1.61B increase.
- Dimensional Fund Advisors's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $331M.
- Dimensional Fund Advisors fully exited AstraZeneca in Q1 2026, selling an estimated $609M.
- Dimensional Fund Advisors's ten largest holdings make up 17% of its $481B portfolio in Q1 2026.
- Dimensional Fund Advisors opened 72 new positions and closed 97 in Q1 2026.
- Dimensional Fund Advisors's portfolio value rose 0.98% quarter-over-quarter to $481B.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.